Bildkälla: Stockfoto

Spago Nanomedical Q3 2022: Tumorad closing in on clinical development - Redeye

Redeye comments on Spago’s Q3 2022 report, and we estimate that the company is closing in on wrapping up its phase I SAGOPIX-01 trial with contrast agent SpagoPix (SN132D) and initiating a phase I/IIa trial with radionuclide drug candidate Tumorad (177Lu-SN201). We review our estimates and make some adjustments to our valuation.

Redeye comments on Spago’s Q3 2022 report, and we estimate that the company is closing in on wrapping up its phase I SAGOPIX-01 trial with contrast agent SpagoPix (SN132D) and initiating a phase I/IIa trial with radionuclide drug candidate Tumorad (177Lu-SN201). We review our estimates and make some adjustments to our valuation.
Börsvärldens nyhetsbrev
ANNONSER